Arena Pharmaceuticals, Inc.
Jan 7, 2003

Arena Pharmaceuticals, Inc. To Provide Telephone and Internet Access for Fourth Quarter Earnings Conference Call Monday, January 20, 2003 Live At 4:30 P.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2003--Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today that it will host both a telephone and internet fourth quarter conference call on Monday, January 20, 2003 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). The Company will release financial results for the fourth quarter that afternoon after the market closes.

Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial officer, will discuss the fourth quarter results, the progress of Arena's collaborations, Project Genesis and other topics. A Question and Answer session will follow the presentation. To access by telephone, dial in toll free at (800) 450-0785 (the international dial in number is (612) 332-0523), and specify that you would like to join the "Fourth Quarter Earnings Conference Call." To access the call via the Internet, go to www.arenapharm.com and click on "Investor Relations." Then, click on "Calendar of Events." The conference call will be listed at the top of the page. Click on the "Live Webcast" link. Then, follow the links and instructions provided. Listening to the conference call on the Internet will require speakers and Microsoft Windows Media Player. An archive of the webcast will be available on Arena's website until January 27, 2003.

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

Arena is a biopharmaceutical company focusing on G protein-coupled receptors.